Strong organic growth expected in 2026, driven by advanced diagnostics and partnerships
Quest Diagnostics reported strong Q4 2025 with double-digit revenue and EPS growth, driven by organic volume gains in physician, hospital, and consumer channels. Management provided 2026 guidance of 6-7% revenue growth and expanding margins, despite weather headwinds and dilution from large hospital partnerships. Key cross-company signals include scaling of Fresenius dialysis testing, re-entry into Elevance networks, and partnerships with Grail and Guardant for oncology testing logistics. Organic revenue growth of 6.4% in Q4, with volume up 7.9% (4.1% ex-Fresenius/Corwell).
Buzzberg readStrong organic growth expected in 2026, driven by advanced diagnostics and partnershipsQuest Diagnostics reported strong Q4 2025 with double-digit revenue and EPS growth, driven by organic volume gains in physician, hospital, and consumer channels. Management provided 2026 guidance of 6-7% revenue growth and expanding margins, despite weather headwinds and dilution from large hospital partnerships. Key cross-company signals include scaling of Fresenius dialysis testing, re-entry into Elevance networks, and partnerships with Grail and Guardant for oncology testing logistics. Organic revenue growth of 6.4% in Q4, with volume up 7.9% (4.1% ex-Fresenius/Corwell).Read full analysisCollapse analysis
Quest Diagnostics reported strong Q4 2025 with double-digit revenue and EPS growth, driven by organic volume gains in physician, hospital, and consumer channels. Management provided 2026 guidance of 6-7% revenue growth and expanding margins, despite weather headwinds and dilution from large hospital partnerships. Key cross-company signals include scaling of Fresenius dialysis testing, re-entry into Elevance networks, and partnerships with Grail and Guardant for oncology testing logistics. Organic revenue growth of 6.4% in Q4, with volume up 7.9% (4.1% ex-Fresenius/Corwell).
Fresenius and Corwell partnerships drive high volume at lower revenue per requisition but are profit-accretive over time.
AI, capex & demand read
AI
Platform & monetization
Management emphasized using AI and automation to drive operational excellence, including a virtual AI agent that reduced routine logistics calls by up to 50% and a new AI logistics tool expected to reduce courier transportation times. They also mentioned partnerships with AI-based companies to better use data for health insights, but did not provide specifics on monetization or demand.
Demand
Bookings & conversion
Management issued guidance for 6-7% revenue growth and expanding margins, backed by strong organic volume, advanced diagnostics momentum, and consumer channel growth, despite weather headwinds.
Capex
Investment and capacity
Capital expenditures are expected to be approximately $550 million in 2026, consistent with 2025 levels. The investment supports ongoing automation, AI deployment, and infrastructure, including the construction of a state-of-the-art laboratory with Corewell Health.
Tone · Confident
Management expressed confidence in 2026 guidance, citing strong organic growth drivers, strategic partnerships, and continued execution, while acknowledging headwinds like weather and PAMA uncertainty.
Supply-chain alpha
A1
Corwell Health CoLab adds $250M of organic revenue at low single-digit margins in 2026, improving to low-teens in 2027, indicating near-term margin dilution but long-term accretion.
“Corwell will add approximately $250 million in organic revenue at low single-digit margins in 2026.”
Haystack MRD test reimbursement progress: Novitas PLA code adjudicated successfully; waiting on MolDx for Medicare Advantage coverage expansion.
“Novitas is the MAC that we submit to, and it did receive a PLA code. It received a reimbursement. We continue to adjudicate through Novitas and are successful there.”
Quest's virtual AI agent reduced routine logistics calls by up to 50%, and a new AI logistics tool is expected to cut courier transportation times in 2026.
“our virtual AI agent has reduced routine logistics calls by up to 50%, and we expect a new AI logistics tool will help us reduce courier transportation times as we roll it out this year.”
Quest has scaled operations for Fresenius, indicating strong demand for dialysis testing services; Fresenius benefits from Quest's expanded capacity and water purity testing.
“we scaled our lab testing to serve more than 200,000 patients at Fresenius Medical Care's dialysis centers in the United States.”
Jim DavisChairman, Chief Executive Officer and President
… and data analytics. In the physician channel, we delivered high single-digit organic revenue growth in the fourth quarter on broad-based demand for our clinical solutions, including several areas of advanced diagnostics and from geographic expansion resulting from increased health plan access. We also grew revenues in enterprise accounts as we added new customers and extended business with existing customers. In addition, during the quarter, we scaled our lab testing to serve more than 200,000 patients at Fresenius Medical Care's dialysis centers in the United States. We also added water purity testing capabilities to our menu to support dialysis customers nationwide. In the hospital channel revenues grew low single digits with collaborative lab solutions driving our growth in the quarter. Our co lab solutions furnace our lab and process management expertise to optimize quality and drive cost efficiencies in areas ranging from hospital lab and supply chain management to analytics and blood utilization. At the start of 2026, we began to scale our CoLab solutions across all 21 hospitals of Corwell Health, a leading health system in Michigan, and our largest implementation of …
Quest provides phlebotomy logistics for Grail's multi-cancer early detection test, representing a modest but growing revenue stream and validating Grail's clinical deployment.
“we have a partnership with Grail. We will do the blood draws for Grail.”
Sorry for the issue earlier. Can we dig into some of the consumer testing dynamics in the environment that you're seeing? You've launched several new partnerships, new initiatives, HIMSS, Aura, Function Health. Can you speak to some of the sustainability of growth across this segment, the margin profile? Are you seeing anything new or different in terms of consumer utilization trends across this segment? And how should we think about what's embedded in guidance in 2026 on this front? Thanks.
Management answer
Jim DavisChairman, Chief Executive Officer and President
Thanks. Yeah, so there's a lot there, Tycho. Look, with respect to Haystack reimbursement, Novitas is the MAC that we submit to, and it did receive a PLA code. It received a reimbursement. We continue to adjudicate through Novitas and are successful there. With respect to Medicare Advantage, we're still waiting on the MOL-DX tech assessment. Once that tech assessment is complete, the first, we will be well positioned with the Medicare Advantage plans. And then, you know, look, we're having ongoing discussions with all the major payers in terms of commercial reimbursement. In some cases, we get paid. In other cases, you don't. We appeal them all. We have doctors write letters around medical necessity, and we continue to make progress on that. But the flow MRD is an ultra-sensitive flow test that has incredibly good sensitivity specificity, and we think it is very, very competitive with you know, with next-gen sequencing-based tests. We're very confident of that. We'll continue to do studies to show that. The value proposition is really around speed. So, as you know, patients with myeloma, you know, that disease moves very, very quickly. Speed is of the essence, and we can get an answer back within three days. It's also a significantly lower-cost test, so from a reimbursement standpoint, it'll offer payers a choice that will offer physicians and patients a choice to have a test that is highly comparable with the next-gen sequencing test at, again, a turnaround time that is very, very short, three days, not weeks, and with, again, ultra, you know, good sensitivity specificity. In terms of the multi-cancer early detection tests, Yes, we have a partnership with Grail. We will do the blood draws for Grail. We've listed it in our test compendium, and Grail obviously pays us to do those draws and handle the logistics for them. And then we did announce a partnership to draw for the garnet colon cancer-based blood screening test, and that will be underway later in the first quarter.
Sorry for the issue earlier. Can we dig into some of the consumer testing dynamics in the environment that you're seeing? You've launched several new partnerships, new initiatives, HIMSS, Aura, Function Health. Can you speak to some of the sustainability of growth across this segment, the margin profile? Are you seeing anything new or different in terms of consumer utilization trends across this segment? And how should we think about what's embedded in guidance in 2026 on this front? Thanks.
Management answer
Jim DavisChairman, Chief Executive Officer and President
Thanks. Yeah, so there's a lot there, Tycho. Look, with respect to Haystack reimbursement, Novitas is the MAC that we submit to, and it did receive a PLA code. It received a reimbursement. We continue to adjudicate through Novitas and are successful there. With respect to Medicare Advantage, we're still waiting on the MOL-DX tech assessment. Once that tech assessment is complete, the first, we will be well positioned with the Medicare Advantage plans. And then, you know, look, we're having ongoing discussions with all the major payers in terms of commercial reimbursement. In some cases, we get paid. In other cases, you don't. We appeal them all. We have doctors write letters around medical necessity, and we continue to make progress on that. But the flow MRD is an ultra-sensitive flow test that has incredibly good sensitivity specificity, and we think it is very, very competitive with you know, with next-gen sequencing-based tests. We're very confident of that. We'll continue to do studies to show that. The value proposition is really around speed. So, as you know, patients with myeloma, you know, that disease moves very, very quickly. Speed is of the essence, and we can get an answer back within three days. It's also a significantly lower-cost test, so from a reimbursement standpoint, it'll offer payers a choice that will offer physicians and patients a choice to have a test that is highly comparable with the next-gen sequencing test at, again, a turnaround time that is very, very short, three days, not weeks, and with, again, ultra, you know, good sensitivity specificity. In terms of the multi-cancer early detection tests, Yes, we have a partnership with Grail. We will do the blood draws for Grail. We've listed it in our test compendium, and Grail obviously pays us to do those draws and handle the logistics for them. And then we did announce a partnership to draw for the garnet colon cancer-based blood screening test, and that will be underway later in the first quarter.
🍪 Cookies
We use cookies to operate this site and for analytics. Declining won't affect your access to content.